Nosopharm, a Lyon, France-based company dedicated to the research and development of new anti-infective drugs, received €1m ($1.2M) in funding.
Bpifrance provided the funding in the form of an interest-free loan.
The company will use the proceeds from the loan to undertake chemistry, manufacturing and controls (CMC) development and regulatory preclinical research for its main drug candidate, NOSO-502 and to submit a clinical trial authorisation application in 2019 with a view to beginning the first clinical trials in humans in 2020.
Founded in 2009 and led by Philippe Villain-Guillot, CEO, Nosopharm is a biotechnology company specialized in the research and development of new antimicrobial molecules. The company discovered and developed NOSO-502, a first-in-class antibiotic for the treatment of multidrug-resistant hospital-acquired infections. It has developed a unique expertise in the discovery of natural bioactive products stemming from the Xenorhadbus and Photorhabdus microbial genera and in the medicinal chemistry of Odilorhabdins, the new class of antibiotics to which NOSO-502 belongs.
Nosopharm has a staff of eight.
To date, the company has raised a total of €4.3M ($5.2M) in private equity and received €3.8M ($4.6M) in grants from Bpifrance, IMI, DGA, Region Languedoc-Roussillon and FEDER.